Protalix BioTherapeutics, Inc Form 8-K February 16, 2017			
UNITED STATES			
SECURITIES AND EXCH.	ANGE COMMISSION		
Washington, D.C. 20549			
FORM 8-K			
CURRENT REPORT			
Pursuant to Section 13 or 13	5(d) of		
the Securities Exchange Act	t of 1934		
Date of Report (Date of Ear	liest Event Reported): Febru	ary 16, 2017	
Protalix BioTherapeutics, I	nc.		
(Exact name of registrant as	s specified in its charter)		
Delaware (State or other jurisdiction	001-33357	65-0643773 (IRS Employer	
of incorporation)	(Commission File Number)	Identification No.)	

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

2 Snunit Street 20100 Science Park, POB 455 Carmiel, Israel (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

<sup>&</sup>quot;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

<sup>&</sup>quot;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

<sup>&</sup>quot;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

<sup>&</sup>quot;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item 7.01. Regulation FD Disclosure

On February 13, 2017, Protalix BioTherapeutics, Inc. (the "Company") announced that the Company was going to participate in the Lysosomal Disease Network 13<sup>th</sup> Annual WORLD*Symposium*<sup>TM</sup> 2017 being held February 13 through 17, 2017 in San Diego, CA. Positive data from the Company's phase I/II dose-ranging clinical trial of PRX-102 for the treatment of Fabry disease was presented at the symposium.

Dr. Yoseph Shaaltiel, the Company's Executive Vice President, Research & Development, gave an oral presentation entitled "Characterization of a chemically modified plant cell culture expressed human -galactosidase-A enzyme for treatment of Fabry disease."

Dr. Derralynn Hughes of the Lysosomal Storage Disease Unit, Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, London, UK, and a principal investigator in the Company's clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease, gave an oral presentation entitled "One-year follow up of Fabry disease patients treated by IV administration of a plant derived alpha-Gal-A enzyme: safety and efficacy." Dr. Hughes also gave a poster presentation of the same title.

Prof. David Warnock, Professor of Nephrology at the University of Alabama Birmingham, Birmingham, Alabama, gave an oral presentation entitled "PRX-102 for treating Fabry disease – immunogenicity and PK results from a phase 1-2 study." Prof. Warnock also gave a poster presentation of the same title.

The presentations and posters featuring the data will be available on the Company's website, under the Presentations tab.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## **PROTALIX** BIOTHERAPEUTICS, INC.

Date: February 16, 2017 By: /s/ Moshe Manor

Name: Moshe Manor

Title: President and

Chief Executive Officer